Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) Stock Competitors & Peer Comparison
See CUVL's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CUVL and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CUVL | $5.59 | -3.62% | 281.4M | 12.04 | $0.46 | N/A |
| RPRX | $56.93 | +0.30% | 24.9B | 10.71 | $5.25 | +1.63% |
| CORT | $121.19 | +1.33% | 12.8B | 338.69 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| KNSA | $79.78 | +2.33% | 6B | 81.19 | $0.97 | N/A |
| LQDA | $27.38 | +2.62% | 2.5B | 20.45 | $1.37 | N/A |
| PBH | $48.23 | +1.39% | 2.3B | 10.82 | $4.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| LTGO | $16.00 | +3.09% | 889.7M | -5.87 | -$2.52 | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
CUVL vs RPRX Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, RPRX has a market cap of 24.9B. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while RPRX trades at $56.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas RPRX's P/E ratio is 10.71. In terms of profitability, CUVL's ROE is N/A, compared to RPRX's ROE of +0.12%. Regarding short-term risk, CUVL is less volatile compared to RPRX. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check RPRX's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
CUVL vs CORT Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, CORT has a market cap of 12.8B. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while CORT trades at $121.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas CORT's P/E ratio is 338.69. In terms of profitability, CUVL's ROE is N/A, compared to CORT's ROE of +0.08%. Regarding short-term risk, CUVL is less volatile compared to CORT. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
CUVL vs WBA Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas WBA's P/E ratio is -1.64. In terms of profitability, CUVL's ROE is N/A, compared to WBA's ROE of -0.57%. Regarding short-term risk, CUVL is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check WBA's competition here
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA)
CUVL vs KNSA Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, KNSA has a market cap of 6B. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while KNSA trades at $79.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas KNSA's P/E ratio is 81.19. In terms of profitability, CUVL's ROE is N/A, compared to KNSA's ROE of +0.14%. Regarding short-term risk, CUVL is less volatile compared to KNSA. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check KNSA's competition here
Liquidia Corporation (NASDAQ: LQDA)
CUVL vs LQDA Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, LQDA has a market cap of 2.5B. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while LQDA trades at $27.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas LQDA's P/E ratio is 20.45. In terms of profitability, CUVL's ROE is N/A, compared to LQDA's ROE of +1.50%. Regarding short-term risk, CUVL is less volatile compared to LQDA. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check LQDA's competition here
Prestige Consumer Healthcare Inc. (NYSE: PBH)
CUVL vs PBH Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, PBH has a market cap of 2.3B. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while PBH trades at $48.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas PBH's P/E ratio is 10.82. In terms of profitability, CUVL's ROE is N/A, compared to PBH's ROE of +0.09%. Regarding short-term risk, CUVL is less volatile compared to PBH. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check PBH's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
CUVL vs HROWL Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas HROWL's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to HROWL's ROE of -1.04%. Regarding short-term risk, CUVL is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
CUVL vs HROWM Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas HROWM's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to HROWM's ROE of -1.04%. Regarding short-term risk, CUVL is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check HROWM's competition here
Latigo Biotherapeutics Inc. (NASDAQ: LTGO)
CUVL vs LTGO Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, LTGO has a market cap of 889.7M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while LTGO trades at $16.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas LTGO's P/E ratio is -5.87. In terms of profitability, CUVL's ROE is N/A, compared to LTGO's ROE of N/A. Regarding short-term risk, CUVL is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check LTGO's competition here
Helus Pharma Inc. (NASDAQ: HELP)
CUVL vs HELP Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, HELP has a market cap of 664.5M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while HELP trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas HELP's P/E ratio is -2.57. In terms of profitability, CUVL's ROE is N/A, compared to HELP's ROE of -0.71%. Regarding short-term risk, CUVL is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check HELP's competition here
Sinovac Biotech Ltd. (NASDAQ: SVA)
CUVL vs SVA Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while SVA trades at $6.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas SVA's P/E ratio is -5.68. In terms of profitability, CUVL's ROE is N/A, compared to SVA's ROE of -0.01%. Regarding short-term risk, CUVL is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check SVA's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
CUVL vs CELG-RI Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, CELG-RI has a market cap of 233.9M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while CELG-RI trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to CELG-RI's ROE of N/A. Regarding short-term risk, CUVL is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check CELG-RI's competition here
High Tide Inc. (NASDAQ: HITI)
CUVL vs HITI Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, HITI has a market cap of 226.7M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while HITI trades at $2.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas HITI's P/E ratio is -9.53. In terms of profitability, CUVL's ROE is N/A, compared to HITI's ROE of -0.36%. Regarding short-term risk, CUVL is less volatile compared to HITI. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check HITI's competition here
Electra Therapeutics Inc. (NASDAQ: ETRA)
CUVL vs ETRA Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, ETRA has a market cap of 193.9M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while ETRA trades at $9.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas ETRA's P/E ratio is -3.45. In terms of profitability, CUVL's ROE is N/A, compared to ETRA's ROE of N/A. Regarding short-term risk, CUVL is less volatile compared to ETRA. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check ETRA's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
CUVL vs CTOR Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, CTOR has a market cap of 78.9M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while CTOR trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas CTOR's P/E ratio is -1.81. In terms of profitability, CUVL's ROE is N/A, compared to CTOR's ROE of -1.03%. Regarding short-term risk, CUVL is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check CTOR's competition here
Atlantic International Corp. (NASDAQ: ATLN)
CUVL vs ATLN Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while ATLN trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas ATLN's P/E ratio is -0.68. In terms of profitability, CUVL's ROE is N/A, compared to ATLN's ROE of -83.20%. Regarding short-term risk, CUVL is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check ATLN's competition here
Rite Aid Corporation (NYSE: RAD)
CUVL vs RAD Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas RAD's P/E ratio is -0.05. In terms of profitability, CUVL's ROE is N/A, compared to RAD's ROE of +2.76%. Regarding short-term risk, CUVL is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
CUVL vs GLTO Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas GLTO's P/E ratio is -1.78. In terms of profitability, CUVL's ROE is N/A, compared to GLTO's ROE of -0.83%. Regarding short-term risk, CUVL is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check GLTO's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
CUVL vs NSRX Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, NSRX has a market cap of 30.9M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while NSRX trades at $3.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas NSRX's P/E ratio is -4.99. In terms of profitability, CUVL's ROE is N/A, compared to NSRX's ROE of -1.59%. Regarding short-term risk, CUVL is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check NSRX's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
CUVL vs SCYX Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, SCYX has a market cap of 26.5M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while SCYX trades at $4.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas SCYX's P/E ratio is -1.23. In terms of profitability, CUVL's ROE is N/A, compared to SCYX's ROE of -0.21%. Regarding short-term risk, CUVL is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check SCYX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
CUVL vs COSM Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, COSM has a market cap of 17.1M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while COSM trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas COSM's P/E ratio is -0.43. In terms of profitability, CUVL's ROE is N/A, compared to COSM's ROE of -1.19%. Regarding short-term risk, CUVL is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check COSM's competition here
Cerenome, Inc. (NASDAQ: CNSY)
CUVL vs CNSY Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, CNSY has a market cap of 12.3M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while CNSY trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas CNSY's P/E ratio is -0.43. In terms of profitability, CUVL's ROE is N/A, compared to CNSY's ROE of -3.94%. Regarding short-term risk, CUVL is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check CNSY's competition here
Biofrontera Inc. (NASDAQ: BFRI)
CUVL vs BFRI Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, BFRI has a market cap of 11.8M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while BFRI trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas BFRI's P/E ratio is -1.67. In terms of profitability, CUVL's ROE is N/A, compared to BFRI's ROE of -1.28%. Regarding short-term risk, CUVL is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check BFRI's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
CUVL vs CJJD Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas CJJD's P/E ratio is -0.46. In terms of profitability, CUVL's ROE is N/A, compared to CJJD's ROE of -0.25%. Regarding short-term risk, CUVL is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
CUVL vs SSY Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas SSY's P/E ratio is -2.86. In terms of profitability, CUVL's ROE is N/A, compared to SSY's ROE of -0.09%. Regarding short-term risk, CUVL is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check SSY's competition here
Scienture Holdings, Inc. (NASDAQ: SCNX)
CUVL vs SCNX Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, SCNX has a market cap of 6.3M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while SCNX trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas SCNX's P/E ratio is -1.84. In terms of profitability, CUVL's ROE is N/A, compared to SCNX's ROE of -0.54%. Regarding short-term risk, CUVL is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check SCNX's competition here
POMDOCTOR Ltd (NASDAQ: POM)
CUVL vs POM Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, POM has a market cap of 5.4M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while POM trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas POM's P/E ratio is -0.11. In terms of profitability, CUVL's ROE is N/A, compared to POM's ROE of +0.16%. Regarding short-term risk, CUVL is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check POM's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
CUVL vs BGMS Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, BGMS has a market cap of 4.5M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while BGMS trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas BGMS's P/E ratio is -0.23. In terms of profitability, CUVL's ROE is N/A, compared to BGMS's ROE of -0.32%. Regarding short-term risk, CUVL is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check BGMS's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
CUVL vs BFRIW Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, BFRIW has a market cap of 4.3M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while BFRIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas BFRIW's P/E ratio is -0.01. In terms of profitability, CUVL's ROE is N/A, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, CUVL is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check BFRIW's competition here
Eocene Ltd. (NASDAQ: EOCN)
CUVL vs EOCN Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, EOCN has a market cap of 3.8M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while EOCN trades at $3.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas EOCN's P/E ratio is -0.26. In terms of profitability, CUVL's ROE is N/A, compared to EOCN's ROE of N/A. Regarding short-term risk, CUVL is less volatile compared to EOCN. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check EOCN's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
CUVL vs PAVS Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, PAVS has a market cap of 3.1M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while PAVS trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas PAVS's P/E ratio is -0.04. In terms of profitability, CUVL's ROE is N/A, compared to PAVS's ROE of -0.46%. Regarding short-term risk, CUVL is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check PAVS's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
CUVL vs MDVL Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas MDVL's P/E ratio is -0.05. In terms of profitability, CUVL's ROE is N/A, compared to MDVL's ROE of -2.39%. Regarding short-term risk, CUVL is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
CUVL vs ATNFW Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas ATNFW's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, CUVL is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
CUVL vs BGMSP Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, CUVL's ROE is N/A, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, CUVL is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check BGMSP's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
CUVL vs AZNH Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas AZNH's P/E ratio is 38.35. In terms of profitability, CUVL's ROE is N/A, compared to AZNH's ROE of +0.00%. Regarding short-term risk, CUVL is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check AZNH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
CUVL vs LFLYW Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, CUVL's ROE is N/A, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, CUVL is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check LFLYW's competition here
ProPhase Labs, Inc. (NASDAQ: PRPH)
CUVL vs PRPH Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, PRPH has a market cap of 140.2K. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while PRPH trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas PRPH's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to PRPH's ROE of -13.59%. Regarding short-term risk, CUVL is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check PRPH's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
CUVL vs CPD Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, CPD has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas CPD's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to CPD's ROE of N/A. Regarding short-term risk, CUVL is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check CPD's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
CUVL vs ESRX Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, ESRX has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas ESRX's P/E ratio is 10.69. In terms of profitability, CUVL's ROE is N/A, compared to ESRX's ROE of +0.26%. Regarding short-term risk, CUVL is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check ESRX's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
CUVL vs IPXL Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, IPXL has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas IPXL's P/E ratio is -10.11. In terms of profitability, CUVL's ROE is N/A, compared to IPXL's ROE of -1.16%. Regarding short-term risk, CUVL is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check IPXL's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
CUVL vs OREX Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, OREX has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas OREX's P/E ratio is -0.14. In terms of profitability, CUVL's ROE is N/A, compared to OREX's ROE of -0.54%. Regarding short-term risk, CUVL is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check OREX's competition here
POZEN Inc. (NASDAQ: POZN)
CUVL vs POZN Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, POZN has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas POZN's P/E ratio is N/A. In terms of profitability, CUVL's ROE is N/A, compared to POZN's ROE of +0.61%. Regarding short-term risk, CUVL is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for CUVL.Check POZN's competition here
Shire plc (NASDAQ: SHPG)
CUVL vs SHPG Comparison October 2026
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CUVL stands at 281.4M. In comparison, SHPG has a market cap of 0. Regarding current trading prices, CUVL is priced at $5.59 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CUVL currently has a P/E ratio of 12.04, whereas SHPG's P/E ratio is 11.35. In terms of profitability, CUVL's ROE is N/A, compared to SHPG's ROE of +0.13%. Regarding short-term risk, CUVL is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for CUVL.Check SHPG's competition here